Triangle biopharma raises $350M in funding through two deals
BioCryst Pharmaceuticals has landed $350 million in cash through two deals that the company says positions it for the global launch of one drug and advancement of another.
Read More
biocryst
Earnings news: Duke Energy, CommScope, BioCryst, Chimerix
Duke Energy, CommScope and two biotech firms in the Triangle report their financials as earnings season continues.
Read More
Earnings news: CommScope, Biocryst, BDSI, Chimerix, Aerie, VTV,
A host of companies across North Carolina are reporting earnings this week, including CommScope, Biocryst, BDSI and more. Here’s a look:
Read More
Durham pharma firm Biocryst pulls plug on COVID-19 efforts
BioCryst Pharmaceuticals is developing its drug galidesivir as a potential treatment for more than 20 RNA viruses. But SARS-CoV-2, the virus that causes COVID-19, will no longer be one of them. Here’s what’s happening.
Read More
FDA approves BioCryst drug to treat HAE swelling disorder; stock jumps 14%
Shares in Triangle pharmaceutical firm BioCryst surged 14% Friday morning after the company disclosed FDA approval of its drug to treat a rare swelling disorder.
Read More
NC life science bloodbath: BioDelivery in the black but BioCryst, Aerie, TransEnterix, Chimerix, vTv report big losses
Thursday was not a good day for North Carolina life science companies. While BioDelivery Sciences reported a big profit, BioCryst, Aerie, TransEnterix, Chimerix and vTv Therapeutics all reported signifcant losses.
Read More
Biocryst treatment for genetic disease HAE lands early access approval in UK
With a regulatory agency’s positive opinion, hereditary angioedema patients in the U.K. aged 12 years and older can gain access to Biocryst’s berotralstat for the routine prevention of recurrent attacks of HAE before the drug is granted marketing authorization by the European Commission.
Read More
RTP biotech BioCryst receives $7M order from feds for influenza therapy
Just days after landing a $44 million contract to see if its investigational anti-viral drug, galidesivir, is effective in treating the COVID-19 coronavirus, BioCryst has secured a $7 million order from the federal government for its influenza therapy known as Rapivab.
Read More
Durham’s BioCryst lands $44M contract to test anti-viral drug against COVID-19 virus
BioCryst said galidesivir has demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including the coronaviruses that cause MERS and SARS.
Read More
